<DOC>
	<DOCNO>NCT00232479</DOCNO>
	<brief_summary>Dose dense therapy show increase survival adjuvant set breast cancer . It unknown dose dense therapy improve survival tumor express her-2 . This study evaluate neoadjuvant regimen contain carboplatin , taxotere herceptin use dose dense manner patient large breast cancer . The endpoint pathologic complete response use surrogate marker survival .</brief_summary>
	<brief_title>Dose Dense Carboplatin , Taxotere Herceptin As Primary Systemic Therapy Breast Cancer</brief_title>
	<detailed_description>Dose dense therapy show increase survival adjuvant set breast cancer . It unknown dose dense therapy improve survival tumor express her-2 . This study evaluate neoadjuvant regimen contain carboplatin , taxotere herceptin use dose dense manner patient large breast cancer . The endpoint pathologic complete response use surrogate marker survival.Safety tolerability assess number grade 4 toxicity hospitalization</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>HER2 overexpressing breast cancer Clinical stage 23B Normal ejection fraction Metastatic disease Low ejection fraction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>